Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Revenue (2018 - 2023)

Denali Therapeutics (DNLI) has disclosed Revenue for 6 consecutive years, with $319.3 million as the latest value for Q4 2023.

  • On a quarterly basis, Revenue rose 1388004.35% to $319.3 million in Q4 2023 year-over-year; TTM through Sep 2024 was $319.3 million, a 670.59% increase, with the full-year FY2023 number at $330.5 million, up 9627.22% from a year prior.
  • Revenue was $319.3 million for Q4 2023 at Denali Therapeutics, up from $1.3 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $319.3 million in Q4 2023 to a low of -$89.1 million in Q3 2022.
  • A 5-year average of $22.1 million and a median of $6.6 million in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: crashed 1786.0% in 2022, then surged 1388004.35% in 2023.
  • Denali Therapeutics' Revenue stood at $26.4 million in 2019, then tumbled by 170.68% to -$18.7 million in 2020, then soared by 167.09% to $12.5 million in 2021, then tumbled by 99.82% to $23000.0 in 2022, then soared by 1388004.35% to $319.3 million in 2023.
  • Per Business Quant, the three most recent readings for DNLI's Revenue are $319.3 million (Q4 2023), $1.3 million (Q3 2023), and $5.0 million (Q2 2023).